Summary
Gilead Sciences, Inc. reported strong financial performance for the first quarter of 2010, driven by robust product sales, particularly in its antiviral and HIV/AIDS portfolio. Total revenues increased significantly year-over-year, bolstered by substantial growth in Atripla and Truvada sales, along with a notable surge in royalty revenues primarily from Tamiflu. The company demonstrated healthy operating income and net income, with solid cash flow generation from operations. While overall financial health appears strong, investors should note the increasing impact of healthcare reform legislation in the U.S., which is projected to reduce product sales. Additionally, the company continues to invest heavily in research and development, leading to increased operating expenses. Despite these factors, Gilead Sciences remains a dominant player in its therapeutic areas, with a strong cash position and ongoing strategic initiatives including share repurchases.
Financial Highlights
48 data points| Revenue | $2.09B |
| Cost of Revenue | $440.43M |
| Gross Profit | $1.35B |
| SG&A Expenses | $265.62M |
| Operating Expenses | $924.71M |
| Operating Income | $1.16B |
| Interest Expense | $16.95M |
| Net Income | $854.90M |
| EPS (Basic) | $0.47 |
| EPS (Diluted) | $0.46 |
| Shares Outstanding (Basic) | 1.80B |
| Shares Outstanding (Diluted) | 1.86B |
Key Highlights
- 1Total revenues increased by 36% to $2.09 billion for the three months ended March 31, 2010, compared to the same period in 2009.
- 2Product sales grew by 24% to $1.79 billion, driven by a 19% increase in antiviral product sales, notably Atripla (up 36%) and Truvada (up 11%).
- 3Royalty revenues saw a significant increase of 454% to $293.7 million, primarily due to higher Tamiflu royalties from Roche.
- 4Net income attributable to Gilead increased by 45% to $854.9 million, resulting in basic EPS of $0.95 and diluted EPS of $0.92.
- 5Cash, cash equivalents, and marketable securities stood at $4.62 billion as of March 31, 2010, demonstrating a strong liquidity position.
- 6The company repurchased $162.5 million of its common stock during the quarter as part of its ongoing stock repurchase program.
- 7The U.S. healthcare reform legislation enacted in March 2010 is expected to reduce U.S. product sales by approximately $200 million for the full year 2010, with the majority of the impact occurring in the latter half of the year.